HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q4 2016 13F Holders as of 31 Dec 2016

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
110,724,726
Share change
+4,708,068
Total reported value
$1,093,967,390
Put/Call ratio
189%
Price per share
$9.88
Number of holders
164
Value change
+$44,483,048
Number of buys
84
Number of sells
59

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q4 2016

As of 31 Dec 2016, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 164 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 110,724,726 shares. The largest 10 holders included Third Security, LLC, IRIDIAN ASSET MANAGEMENT LLC/CT, VANGUARD GROUP INC, First Eagle Investment Management, LLC, BB BIOTECH AG, FMR LLC, BlackRock Fund Advisors, STATE STREET CORP, BlackRock Institutional Trust Company, N.A., and JPMORGAN CHASE & CO. This page lists 164 institutional shareholders reporting positions in this security for the Q4 2016 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.